Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Biomedical CoTPE:7780 -1.45%23 Return-on-Tangible-Asset is 6.94% as of Mar. 2026, which is 47% below its 10-year median of 13.20. GuruFocus rates TPE:7780 with a GF Score™ of 23/100. The stock has 6 warning signs investors should review. Among 1,997 Consumer Packaged Goods companies, Daiken Biomedical Co ranks better than 81.82% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Daiken Biomedical Co's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$417 Mil. Daiken Biomedical Co's average total tangible assets for the quarter that ended in Mar. 2026 was NT$6,010 Mil. Therefore, Daiken Biomedical Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 6.94%.
The historical rank and industry rank for Daiken Biomedical Co's Return-on-Tangible-Asset or its related term are showing as below:
TPE:7780'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 9.08 Med: 13.2 Max: 25.2
Current: 10.28
During the past 4 years, Daiken Biomedical Co's highest Return-on-Tangible-Asset was 25.20%. The lowest was 9.08%. And the median was 13.20%.
TPE:7780's Return-on-Tangible-Asset is ranked better than 81.82% of 1997
companies
in the Consumer Packaged Goods industry
Industry Median: 3.43
vs TPE:7780: 10.28
Daiken Biomedical Co (TPE:7780) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Daiken Biomedical Co Return-on-Tangible-Asset Related Terms
Daiken Biomedical Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Daiken Biomedical Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiken Biomedical Co Return-on-Tangible-Asset Chart
TPE:7780 vs KHC, GIS: Return-on-Tangible-Asset Comparison
For the Packaged Foods subindustry, Daiken Biomedical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Biomedical Co Return-on-Tangible-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Daiken Biomedical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Daiken Biomedical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 6.94% mean?
Daiken Biomedical Co (TPE:7780) has a Return-on-Tangible-Asset of 6.94% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Daiken Biomedical Co and its competitors. This is 47% below median its historical median of 13.20. Over the past decade, Daiken Biomedical Co's Return-on-Tangible-Asset has ranged from 9.08 to 25.20. According to the industry distribution chart, Daiken Biomedical Co ranks #363 out of 1997 companies in the Consumer Packaged Goods industry, placing it in the top 18.2%.
Is Daiken Biomedical Co's Return-on-Tangible-Asset too high?
Daiken Biomedical Co's current Return-on-Tangible-Asset of 6.94% is 47% below median its 10-year median of 13.20. Over the past 10 years, this metric has ranged from a low of 9.08 to a high of 25.20. The Consumer Packaged Goods industry median Return-on-Tangible-Asset is 3.43. Daiken Biomedical Co's value of 6.94% is 102.3% above this industry median. Based on the distribution chart, Daiken Biomedical Co ranks #363 out of 1997 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Daiken Biomedical Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's Return-on-Tangible-Asset compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Daiken Biomedical Co ranks #363 out of 1997 companies for Return-on-Tangible-Asset. This places Daiken Biomedical Co in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.43. Daiken Biomedical Co's value of 6.94% is 102.3% above this benchmark. Historically, Daiken Biomedical Co's own Return-on-Tangible-Asset has ranged from 9.08 to 25.20 over the past decade. While the company's 10-year median is 13.20 vs. the industry median of 3.43, Daiken Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Consumer Packaged Goods company?
The median Return-on-Tangible-Asset among Consumer Packaged Goods companies is 3.43, based on 1,997 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Biomedical Co's current Return-on-Tangible-Asset of 6.94% is 102.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Daiken Biomedical Co and its competitors. For the Consumer Packaged Goods industry, the median Return-on-Tangible-Asset is 3.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Biomedical Co's current Return-on-Tangible-Asset is 6.94%, which is 47% below median its own 10-year median of 13.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current Return-on-Tangible-Asset of 6.94%. The current Return-on-Tangible-Asset is 6.94%, which is 47% below median its 10-year median of 13.20 and 102.3% above the Consumer Packaged Goods industry median of 3.43. Daiken Biomedical Co's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current Return-on-Tangible-Asset is 6.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
23GF Score
Get the complete analysis for TPE:7780
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7780 has been successfully added to your 
